Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene rebound regression.

Michael Dosik1, Richard Kaufman

  • 1North Shore Hematology/Oncology Associates, East Setauket, New York 11733, USA. Dr.Dosik@optonline.net

Cancer Investigation
|December 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovine Forestomach Matrix in the Surgical Management of Complex Lower-Extremity Soft-Tissue Defects.

Journal of the American Podiatric Medical Association·2023
Same author

Turn it up to 11.

Transfusion·2021
Same author

Sprucing up.

Transfusion·2021
Same author

Altering the landscape of transfusion safety.

Transfusion·2020
Same author

Inflection points.

Transfusion·2020
Same author

Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study.

Transfusion·2020
Same journal

Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

Cancer investigation·2026
Same journal

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Cancer investigation·2026
Same journal

The Association Between Lymphocyte-Monocyte Ratio, Tumor-Infiltrating Lymphocytes, and Tumor-Associated Macrophages with 3-Year Progression-Free Survival in Advanced Local Stage Nasopharyngeal Cancer Patients.

Cancer investigation·2026
Same journal

<i>In Vivo</i> Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles.

Cancer investigation·2026
Same journal

Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.

Cancer investigation·2026
Same journal

Adrenal Carcinoma Laterality is of Limited Clinical Significance: A National Perspective.

Cancer investigation·2026
See all related articles

Withdrawal of raloxifene led to clinical remission in metastatic breast cancer. This case highlights the potential for hormone withdrawal to induce rebound regression, an often-overlooked treatment strategy.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Selective estrogen receptor modulators (SERMs) like raloxifene are used for osteoporosis and breast cancer prevention.
  • Hormonal therapies can influence cancer progression and regression.

Observation:

  • A postmenopausal woman with a history of stage II breast cancer developed metastatic disease after initiating raloxifene for osteopenia.
  • Tumor regression was observed following the discontinuation of raloxifene.

Findings:

  • This case presents the first report of clinical remission in metastatic breast cancer upon raloxifene withdrawal.
  • Raloxifene discontinuation led to the regression of supraclavicular adenopathy and lung metastases.

Implications:

Related Experiment Videos

  • Hormone withdrawal can be a viable, yet underutilized, therapeutic strategy in managing hormone-sensitive cancers.
  • Clinicians should consider the potential impact of SERMs on existing or developing malignancies, even when prescribed for other conditions.